New ideas to understand, diagnose, and treat heparin-induced thrombocytopenia
Official title: New approaches to the pathophysiology, diagnosis and management of heparin-induced thrombocytopenia
Funded at Mayo Clinic Arizona · NIH-11482912 · Data updated 2026-11-12
A Mayo Clinic led study will look at the different kinds of HIT antibodies to improve diagnosis and treatment for people with HIT.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Arizona NIH-funded |
| Lab location | 1 site (Scottsdale, United States) |
| Project start | May 25, 2026 |
| Project end | July 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $249,258 |
| NIH project number | 7R01HL158932-06 |
| Project ID | NIH-11482912 on NIH RePORTER |
Who could benefit from this research
✓Could help
People with suspected or confirmed HIT who have or are at risk for thrombosis.
✕Less likely to help
Patients with HIT who are not enrolled in diagnostic or monoclonal antibody studies may not directly benefit.
What this research studies
This grant focuses on HIT, a dangerous blood-clotting disorder caused by antibodies. Researchers will separate and study different antibody types from patients, create new monoclonal antibodies, and test their effects in a mouse HIT model. The goal is to better distinguish harmful antibodies from harmless ones and to link these findings to more accurate tests and safer, more effective treatments. If successful, these findings could help clinicians tailor therapy and reduce complications for people with HIT.
Why it matters
Potential benefit: Better diagnostic tests and more precise treatments could reduce clots and bleeding risks for people with HIT.
How similar studies have gone: Previous work has advanced understanding of HIT antibodies, but this project aims to categorize antibody classes and link them to outcomes in a translational way.
Where this research is happening
-
Mayo Clinic Arizona
Scottsdale, United States Active
Researchers
- Principal investigator: Padmanabhan, Anand — Mayo Clinic Arizona
- Study coordinator: Padmanabhan, Anand
Related research
Other NIH-funded projects on the same topics.
-
Second-generation BLVRB inhibitors to help chemotherapy patients with low platelets
A new drug candidate is being developed to raise platelet counts in patients whose cancer treatment lowers them, reducing bleeding risk.
-
Immunobiology of vaccine-related clotting after adenovirus vaccines
This research asks how antibodies linked to a rare vaccine-related clotting condition (VITT) interact with specific blood proteins to cause clots after certain COVID-19 vaccines.
-
Understanding and diagnosing Heparin-Induced Thrombocytopenia (HIT)
A project to understand the immune factors behind HIT and develop faster, more accurate tests to help people who need heparin therapy.
-
Fetal and neonatal platelet allergy: understanding why some babies bleed
A study to understand why maternal antibodies cause serious bleeding in babies with FNAIT, using an animal model and human-relevant clues to improve future care for affected families.
-
Molecular mechanisms behind immune-related low platelets and clots in transfusion medicine
This grant supports a team of researchers to understand how immune factors cause low platelets and abnormal clots, with a focus on transfusion medicine and pediatric to adult patients.
-
Animal model proof-of-concept for TAR syndrome treatment
A researcher is testing new ways to treat TAR syndrome by using a mouse model that mimics the human bone and blood problems.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.